
Figure S1. CONSORT 2010 Flow Diagram for SCOPE (individual measures).



SCOPE Target Chronic Conditions	Identified Prior to or during the Study	Intervention Group (<i>n</i> = 164), %	Control Group (<i>n</i> = 214), %
Hypertension	Prior to the study	99 (60.4)	123 (57.5)
only	During the study	26 (15.9)	46 (21.5)
Diabetes	Prior to the study	38 (23.2)	49 (22.9)
only	During the study	17 (10.4)	19 (8.9)
COPD	Prior to the study	12 (7.3)	10 (4.7)
only	During the study	110 (67.1)	132 (61.7)
Had at least one or more of hypertension, diabetes and COPD	Combined	157 (97.5)*	203 (96.7%)**

Table S1. Number of participants with each of the chronic condition and with at least one chronic conditions at baseline.

Footnotes: Participants identified prior to the study was by self-report of having the condition or by self-report of medication intake; participants identified during the study was by baseline biomarker measurements; combined = by both self-report and biomarker measurements * = 3 participants with readings missing, ** = 4 participants with readings missing.

Laboratory Measures (units)	Time- Points	Intervention Mean±SE (N)	Control Mean ±SE (N)	<i>p</i> -Value
HbA1C (%)	Baseline 10-month	6.48±1.29 (N=163) 6.40±1.21 (N=131)	$\begin{array}{r} 6.46 \pm 1.20 \text{ (N=214)} \\ 6.35 \pm 1.20 \text{ (N=152)} \end{array}$	Reference 0.734
(%)	18-month	6.42±1.21 (N=120)	6.40±1.20 (N=138)	0.948
Vitamin B12 (pmol/L)	Baseline 10-month 18-month	$\begin{array}{c} 301.03 \pm 205.46 \\ (N=164) \\ 351.63 \pm 211.91 \\ (N=132) \\ 410.03 \pm 223.84 \\ (N=120) \end{array}$	$\begin{array}{c} 306.81 \pm 158.24 \\ (N=214) \\ 340.49 \pm 182.03 \\ (N=152) \\ 345.22 \pm 136.96 \\ (N=138) \end{array}$	Reference 0.605 0.001 **
Hemoglobin concentration	Baseline	13.11±1.51 (N=163)	13.30±1.30 (N=214)	Reference
(g/dL)	10-month 18-month	13.31±1.40 (N=132) 13.12±1.39 (N=120)	13.41±1.30 (N=152) 13.42±1.32 (N=138)	0.002** 0.846
	Baseline	90.65±5.78 (N=163)	89.67±6.27 (N=214)	Referenc
MCV	10-month	90.74±5.38 (N=132)	89.99±6.59 (N=152)	0.005**
(fl)	18-month	90.32±5.18 (N=120)	89.17±6.42 (N=138)	0.280
Platelets (x10^9/L)	Baseline 10-month 18-month	250.14±59.45 (N=214) 252.98±60.34 (N=132) 264.60±64.00 (N=120)	254.37±67.88 (N=214) 260.63±68.43 (N=152) 268.54±82.53 (N=138)	Reference 0.298 0.945
WBC count	Baseline	6.68±1.76 (N=163)	6.65±1.66 (N=214)	Referenc
(x10^9/L)	10-month 18-month	6.80±1.62 (N=132) 6.79±1.63 (N=120)	6.79±1.72 (N=152) 6.80±1.61 (N=138)	0.455 0.920
	Baseline	4.96±1.02 (N=164)	$5.07 \pm 1.02 \text{ (N=214)}$	Referenc
Total Cholesterol (mmol/L)	10-month	4.91±1.06 (N=132)	5.05±1.09 (N=152)	0.506
· · · · ·	18-month	4.88±0.97 (N=120)	5.01±1.03 (N=138)	0.832
HDL Cholesterol	Baseline	1.54±0.43 (N=164)	1.48±0.35 (N=214)	Referenc
(mmol/L)	10-month	1.51±0.41 (N=132)	1.53±0.40 (N=152)	<0.001**
	18-month	1.53±0.44 (N=120)	1.47±0.35 (N=138)	0.857
LDL Cholesterol	Baseline	2.79±0.84 (N=163)	2.95±0.93 (N=213)	Referenc
(mmol/L)	10-month	2.79±0.87 (N=131)	2.87±0.93 (N=151)	0.456

Table S2. Unadjusted models for physiological and functional measures.

	18-month	2.73±0.77 (N=119)	2.91±0.89 (N=138)	0.758
	Baseline	3.41±0.96 (N=164)	3.59±1.00 (N=214)	Reference
Total Cholesterol/HDL Cholesterol	10-month	3.43±1.08 (N=132)	4.43±0.87 (N=152)	0.003**
(mmol/L)	18-month	3.36±0.98 (N=120)	3.53±0.91 (N=138)	0.967
	Baseline	1.38±0.70 (N=164)	1.44 ±0.78 (N=214)	Reference
Triglycerides	10-month	1.37±0.83 (N=132)	1.44 ±0.72 (N=152)	0.547
(mmol/L)	18-month	1.37±0.85 (N=120)	1.38±0.57 (N=138)	0.591
A 11	Baseline	42.60±2.59 (N=164)	43.44±2.34 (N=214)	Reference
Albumin	10-month	43.65±2.43 (N=132)	44.31±2.55 (N=152)	0.755
(g/L)	18-month	41.94±2.38 (N=120)	42.76±2.55 (N=138)	0.936
Caratinina	Baseline	79.79±46.81 (N=164)	75.43±30.20 (N=214)	Reference
Creatinine	10-month	87.00±75.56 (N=132)	83.77±38.18 (N=152)	0.035*
(umol/L)	18-month	80.26±55.26(N=120)	72.70±26.29 (N=138)	0.838
II in a literation of the second in the second in the second seco	Baseline	0.84±0.23 (N=164)	0.84 ±0.28 (N=214)	Reference
Urine microalbumin to creatinine ratio (ACR)	10-month	0.99±2.45 (N=132)	0.76±1.84 (N=152)	0.279
(mg/dL)	18-month	1.15±2.21 (N=122)	0.87±2.24 (N=137)	0.235
			141.85±19.44	
Blood pressure -Systolic (mmHg)	Baseline 10-month 18-month	140.18±02.24 (N=164) 143.78±21.18 (N=132) 139.98±19.25 (N=122)	$(N=214) \\ 140.53 \pm 18.08 \\ (N=152) \\ 136.61 \pm 17.79 \\ (N=137)$	Referenc 0.130 0.081
	Baseline	77.88±12.38 (N=164)	78.14±11.97 (N=214)	Referenc
Blood pressure -Diastolic	10-month	78.68 ± 10.46 (N=132)	78.12±9.57 (N=152)	0.824
(mmHg)	18-month	77.52 ± 10.93 (N=122)	76.30±10.21 (N=137)	0.292
	Baseline	70.61±11.83 (N=164)	71.06±11.92 (N=210)	Referenc
Pulse	10-month	70.48±10.46 (N=132)	71.21±10.99 (N=151)	0.929
(BPM)	18-month	71.58±11.58 (N=122)	71.61±11.78 (N=136)	0.371
		`` /	225.25±92.04	
Peak expiratory flow reading (L/min)	Baseline 10-month 18-month	230.25±95.13 (N=163) 244.18±96.43 (N=130) 243.43±104.52 (N=118)	$(N=214)$ 263.08 ± 101.46 $(N=152)$ 255.61 ± 122.66 $(N=134)$	Reference 0.303 0.439
	Baseline	24.13±4.73 (N=163)	24.52±4.98 (N=210)	Referenc
BMI (kg/m2)	Dasenne	$27.13 \pm 7.73 (11 - 103)$		

	18-month	24.34±4.52 (N=117)	25.38±13.49 (N=133)	0.392
Weight circumference (cm)	Baseline 10-month 18-month	88.28±12.68 (N=164) 95.38±80.30 (N=131) 118.50±163.22 (N=122)	87.88±12.44 (N=214) 124.73±178.19 (N=152) 128.28±187.37 (N=137)	Reference 0.023* 0.880
Time for completing chair-stand test (seconds)	Baseline	13.39±4.55 (N=150)	11.78±3.90 (N=194)	Reference
	10-month	10.86±2.23 (N=121)	11.79±3.94 (N=144)	<0.001***
	18-month	10.66±3.61 (N=110)	11.56±4.53 (N=128)	<0.001***
Difference in oxygen saturation after chair-stand test (%)	Baseline 10-month 18-month	-0.46±1.62 (N=150) -0.26±1.59 (N=121) -0.26±1.59 (N=110)	0.10±1.33 (N=195) -0.33±1.34 (N=144) -0.41±1.27 (N=128)	Reference 0.068 0.007 **
Difference in heart rate after chair-stand test (BPM)	Baseline	9.93±7.99 (N=150)	10.51±6.32 (N=195)	Reference
	10-month	11.64±6.92 (N=121)	9.50±6.74 (N=144)	0.054
	18-month	9.61±6.87 (N=110)	10.71±8.03 (N=128)	0.532
Hand grip strength (kg)	Baseline 10-month 18-month	20.98±6.79 (N=155) 22.66±7.33 (N=126) 21.69±5.83 (N=111)	19.77±6.32 (N=203) 22.34±7.59 (N=150) 21.38±7.26 (N=142)	Reference 0.290 0.122
iADL	Baseline	0.330±0.08 (N=164)	0.33±0.07 (N=214)	Reference
	10-month	0.28±0.08 (N=137)	0.30±0.07 (N=185)	0.852
	18-month	0.47±0.09 (N=130)	0.32±0.08 (N=162)	0.304
SRH	Baseline	78.72±27.98 (N=164)	77.39±24.50 (N=214)	Reference
	10-month	73.16±29.53 (N=137)	65.27±25.57 (N=214)	0.845
	18-month	72.34±30.64 (N=130)	14.20±27.04 (N=214)	0.194

Footnotes: HbA1C: hemoglobin A1c; MCV: Mean corpuscular volume; HDL: high-density lipoprotein, LDL: low-density lipoprotein, RBC: red blood cell, WBC: white blood cell, ACR: albumin to creatinine ratio; BMI: body-mass index; BPM= beats per minute; iADL: independent activities of daily living; SRH: self-rated health; * $p \le 0.05$,** $p \le 0.01$,*** $p \le 0.001$.

Table S3. Non-responder analyses of the composite measure for participants retained versus loss to follow up.

a. Gender difference, 10-month

				Participants Retai			<i>p</i> -Value	
	Control or Interventi		on	Follow	-	-		
				Loss to follow-up	Retained	7		
			Count	19	48	67	-	
			% within Gender	28.4%	71.6%	100.0%	-	
		Male	% within Participants retained	26.8%	33.6%	31.3%		
			or loss to follow-up	0.00/	22.40/	21.20/	-	
	Gender		% of Total	8.9%	22.4%	31.3%	-	
			Count	52	95	147	-	
			% within Gender	35.4%	64.6%	100.0%		
Control		Female	% within Participants retained	73.2%	66.4%	68.7%	0.350	
			or loss to follow-up				-	
			% of Total	24.3%	44.4%	68.7%	-	
			Count	71	143	214	_	
			% within Gender	33.2%	66.8%	100.0%	-	
	Total		% within Participants retained	100.0%	100.0%	100.0%		
		or loss						
			% of Total	33.2%	66.8%	100.0%		
			Count	23	37	60		
			% within Gender	38.3%	61.7%	100.0%		
		Male	% within Participants retained	56.1%	30.1%	36.6%	-	
			or loss to follow-up	30.1%	50.1%	30.0%		
	Gender				36.6%	-		
	Gender		Count	18	86	104	-	
			% within Gender	17.3%	82.7%	100.0%	-	
Intervention		Female	% within Participants retained	42.00/	<u>(0.00)</u>	(2.40)	**0.005	
			or loss to follow-up	43.9%	69.9%	63.4%		
			% of Total	11.0%	52.4%	63.4%	-	
		Count % within Gender		41	123	164	_	
				25.0%	75.0%	100.0%		
	Total		% within Participants retained	100.00/	100.00/	100.00/	-	
			or loss to follow-up	100.0%	100.0%	100.0%		
			% of Total	25.0%	75.0%	100.0%	-	

b. Gender difference, 18-month

	Control o	r Interventi	on	Participants Reta Follow		Total	<i>p</i> -Valu	
	Control		011	Loss to Follow- Up	Retained	Totai	<i>p</i> -vaiu	
			Count	29	38	67	_	
			% within Gender	43.3%	56.7%	100.0%	-	
		Male	% within Participants retained or loss to follow-up	31.2%	31.4%	31.3%	-	
	Gender		% of Total	13.6%	17.8%	31.3%	-	
			Count	64	83	147	-	
			% within Gender	43.5%	56.5%	100.0%	- 1.000	
Control		Female	% within Participants retained or loss to follow-up	68.8%	68.6%	68.7%	- 1.000	
			% of Total	29.9%	38.8%	68.7%		
			Count	93	121	214	-	
			% within Gender	43.5%	56.5%	100.0%		
	Total		% within Participants retained or loss to follow-up	100.0%	100.0%	100.0%	-	
			% of Total	43.5%	56.5%	100.0%		
				Count 28	28	32	60	
			% within Gender	46.7%	53.3%	100.0%		
		Male	% within Participants retained or loss to follow-up	50.0%	29.6%	36.6%		
	Gender		% of Total	17.1%	19.5%	36.6%	-	
	Gender		Count	28	76	104		
			% within Gender	26.9%	73.1%	100.0%	_	
Intervention		Female	% within Participants retained or loss to follow-up	50.0%	70.4%	63.4%	*0.01	
			% of Total	17.1%	46.3%	63.4%	-	
			Count	56	108	164		
			% within Gender	34.1%	65.9%	100.0%	-	
	Total		% within Participants retained or loss to follow-up	100.0%	100.0%	100.0%	_	
			% of Total	34.1%	65.9%	100.0%	-	

c. Marital Status difference, 10-month

	Control or	Intervention		Participants Retain Follow-		Total	
				Loss to Follow-Up	Retained		
			Count	36	41	77	
		Unmarrie	% within Marital Status: Married	46.8%	53.2%	100.0%	-
		d	% within Participants retained or loss to follow-up	50.7%	28.7%	36.0%	-
	Marital Status		% of Total	16.8%	19.2%	36.0%	
	Maritar Status		Count	35	102	137	
Control		Married	% within Marital Status: Married	25.5%	74.5%	100.0%	- **0.002
		Marrieu	% within Participants retained or loss to follow-up	49.3%	71.3% 64.0		- ***0.002
			% of Total	16.4%	47.7%	64.0%	-
			Count	71	143	214	
	Total		% within Marital Status: Married	33.2%	66.8%	100.0%	
	Total		% within Participants retained or loss to follow-up	100.0%	100.0%	100.0%	
			% of Total	33.2%	66.8%	100.0%	-
			Count	28	64	92	_
		Unmarrie	% within Marital Status: Married	30.4%	69.6%	100.0%	
		d	% within Participants retained or loss to follow-up	68.3%	52.0%	56.1%	-
	Marital Status		% of Total	17.1%	39.0%	56.1%	-
Intervention	Marital Status		Count	13	59	72	0.101
		Married	% within Marital Status: Married	18.1%	81.9%	100.0%	_
		Married	% within Participants retained or loss to follow-up	31.7%	48.0%	43.9%	_
		% of Total	7.9%	36.0%	43.9%	_	
	Total		Count	41	123	164	_

% within Marital Status: Marrie	25.0%	75.0%	100.0%
% within Participants reta or loss to follow-up	ined 100.0%	100.0%	100.0%
% of Total	25.0%	75.0%	100.0%

d. Marital Status difference, 18-month

	Control or	Intervention		Participants Reta Follow		Total		
	Control or	Intervention		Loss to Follow- Up	Retained			
			Count	45	32	77		
		Unmarrie	% within Marital Status: Married	58.4%	41.6%	100.0%	-	
		d	% within Participants retained or loss to follow-up	48.4%	26.4%	36.0%	_	
	Marital Status		% of Total	21.0%	15.0%	36.0%		
	Marital Status		Count	48	89	137		
	Marr		% within Marital Status: Married	35.0%	65.0%	100.0%	- •••0.00	
Control		Married	% within Participants retained or loss to follow-up	51.6%	73.6%	64.0%	**0.0(
			% of Total	22.4%	41.6%	64.0%		
			Count	93	121	214		
	Total		% within Marital Status: Married	43.5%	56.5%	100.0%	-	
	Total		% within Participants retained or loss to follow-up	100.0%	100.0%	100.0%	-	
			% of Total	43.5%	56.5%	100.0%	-	
			Count	36	56	92		
	Marital Status d	Unmarrie	% within Marital Status: Married	39.1%	60.9%	100.0%	_	
Intervention		d	% within Participants retained or loss to follow-up	64.3%	51.9%	56.1%	0.139	
		· · · · · · · · · · · · · · · · · · ·	% of Total	22.0%	34.1%	56.1%		
		Married	Count	20	52	72	-	

		% within Marital Status: Married	27.8%	72.2%	100.0%
		% within Participants retained or loss to follow-up	35.7%	48.1%	43.9%
		% of Total	12.2%	31.7%	43.9%
		Count	56	108	164
	T-4-1	% within Marital Status: Married	34.1%	65.9%	100.0%
	Total	% within Participants retained or loss to follow-up	100.0%	100.0%	100.0%
		% of Total	34.1%	65.9%	100.0%

Footnotes: *** denotes *p* < 0.001, ** denotes *p* < 0.01, * denotes *p* < 0.05.

Table S4. Statistical models for changes in medication intakes and lifestyle measures across intervention time-points.

Measures	Time- points	Intervention (N = 164) Mean ±SE or n (%)	95% CI	Control (N = 214) Mean ± SE or n (%)	95% CI	Estimate (SE)	95% CI	t	<i>p</i> -Value
Total number of medications taken	Baseline 10-month 18-month	1.84 (0.12) 1.71 (0.12) 1.89 (0.12)	1.594 to 2.077 1.466 to1.949 1.637 to 2.120	1.83 (0.11) 1.68 (0.11) 1.80 (0.11)	1.616- 2.038 1.471- 1.894 1.592- 2.015	Reference -0.02 -0.07	Reference -0.32 to 0.28 -0.36 to 0.24	Reference -0.11 -0.43	Reference 0.28 0.24
Intake of medication for hypertension	Baseline 10-month 18-month	97 (59.1) 83 (50.6) 86 (52.4)	NA	123 (57.5) 109 (50.9) 101 (47.2)	NA	Reference -0.08 0.14	NA	NA	Reference 0.78 0.63
Intake of medication for diabetes	Baseline 10-month 18-month	38 (23.2) 32 (19.5) 8 (4.9)	NA	48 (22.4) 43 (20.1) 6 (2.8)	NA	Reference -0.08 0.15	NA	NA	Reference 0.83 0.68
Intake of medication for COPD & other chronic respiratory conditions	Baseline 10-month 18-month	10 (6.1) 7 (4.3) 0 (0)	NA	9 (4.2) 9 (4.2) 0 (0)	NA	Reference -0.38 0.18	NA	NA	Reference 0.59 0.80
Smoking status	Baseline 10-month 18-month	19 (11.6) 13 (7.9) 15 (9.1)	NA	16 (7.5) 12 (5.6) 12 (5.6)	NA	Reference -0.07 0.01	NA	NA	Reference 0.898 0.992
Physical activities	Baseline	4.22 (0.21)	3.80 to	2.79 (0.19)	2.43 to	Reference	Reference	Reference	Reference

	10-month 18-month	4.42 (0.23) 3.89 (0.24)	4.64 3.96 to 4.87 3.40 to 4.33	3.54 (0.20) 3.91 (0.21)	3.16 3.15 to 3.93 3.49 to 4.32	0.55 1.47	-0.09 to 1.19 0.80 to 2.13	1.68 4.32	0.09 < 0.001 ***
Social activities	Baseline 10-month 18-month	5.90 (0.17) 6.25 (0.19) 7.58 (0.19)	5.57 to 6.24 5.89 to 6.62 7.20 to 7.96	5.92 (0.15) 6.58 (0.16) 6.75 (0.17)	4.32 5.62 to 6.21 6.26 to 6.90 6.41 to 7.09	Reference 0.32 -0.84	Reference -0.37 to 1.00 -1.55 to - 0.14	Reference 0.91 -2.36	Reference 0.36 0.02 *

Footnotes: NA= not applicable; We measured the levels of physical activity by asking three questions: during the past week, even if it was not a typical week for you, how much total time did you spend on each of the following? 1) Stretching or strengthening exercises (Taiji, Qigong, range of motion, using weights, etc.), 2) Walk for exercise purposes, and 3) Participate in vigorous exercise (e.g. jogging, swimming, keep fit or dancing class, etc.). The participants rated the frequencies by which they participated in the three activities on a 5-point scale, ranging from 0 to 4, with a sum of 12. The higher score indicated higher levels of physical activity; We measured the levels of social activity by asking three questions: during the past week, how much total time did you spend on each of the following? 1) Stretching or strengthening exercises (Taiji, Qigong, range of motion, using weights, etc.), 2) Walk for exercise purposes, and 3) Participate in vigorous exercise (e.g. jogging, swimming, keep fit or dancing class, etc.). The participate of physical activity; We measured the levels of social activity by asking three questions: during the past week, how much total time did you spend on each of the following? 1) Stretching or strengthening exercises (Taiji, Qigong, range of motion, using weights, etc.), 2) Walk for exercise purposes, and 3) Participate in vigorous exercise (e.g. jogging, swimming, keep fit or dancing class, etc.). The participants rated the frequencies by which they participated in the three activities on a 5-point scale, ranging from 0 to 4, with a sum of 12. The higher score indicated higher levels of social activity; * $p \le 0.05$, ** $p \le 0.01$, *** $p \le 0.001$.